BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Kucera Pharmaceutical Is Issued U.S. Patent


10/19/2005 5:09:40 PM

WINSTON-SALEM, N.C., Jan. 14 /PRNewswire/ -- The Kucera Pharmaceutical Company announced today the issuance of a patent by the U.S. Patent and Trademark Office entitled "Compositions and Methods for Double-targeting Virus Infections and Targeting Cancer Cells" (6,670,341). "The technology within this patent can improve the efficacy and safety of a number of antiviral, anticancer, and other therapeutic compounds," said Dr. Ronald Fleming, Chief Scientific Officer.

"This is the 6th U.S. patent issued for the company," said Russ H. Read, Kucera CEO. "Our intellectual property base continues to grow. Our team is highly focused on building value through Kucera chemistry and its initial applications in virology and cancer."

Kucera Pharmaceutical Co. (http://www.kucerapharma.com/), a 2001 spin-off of Wake Forest University Health Sciences and the University of North Carolina at Chapel Hill, has in development patented antiviral small molecules. It also has anticancer agents in development.

Kucera is headquartered at the Piedmont Triad Research Park (http://www.ptrp.org/) in downtown Winston-Salem and has laboratories at Phase 3 Properties, Inc. in Durham, N.C.

CONTACT: Russ H. Read, CEO Kucera Pharmaceutical Co. (336) 723-7133 Dr. Ronald A. Fleming Chief Scientific Officer Kucera Pharmaceutical Co. (336) 403-6819

Kucera Pharmaceutical Company

CONTACT: Russ H. Read, CEO, +1-336-723-7133; or Dr. Ronald A. FlemingChief Scientific Officer, +1-336-403-6819, both of Kucera Pharmaceutical Co.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES